Innovative bio-pharmaceutical development company

Industry

Healthcare

Company Type

Biopharmaceutical

Location

US

Size

$12 million

Investment Type

Equity

For important risk and disclaimer information, Click Here.

To Access DataRoom, click Download NDA.

Helping Great Companies Grow

Overview

Innovative bio-pharmaceutical company seeking $12 million of equity. Developing a new and novel pain killer that has been cleared to enter Phase 2 clinical testing. Compound is from a new class of drugs that could be an alternative and potential replacement for classical opioids, which are highly addictive and have many side effects.

  • Based on natural pain killers produced by the human body
  • Trials have shown this drug to be three to four times more potent than morphine – reduced recovery times, reduced side-effects and substantially reduced abuse potential
  • According to the National Institute of Drug Abuse (NIDA), approximately 47,000 people in the US died in 2018 from opioid addiction
  • Massive global market for opioids of about $25 billion
  • Over $20 million invested previously in the company
  • Led by team of experienced drug industry professionals and renowned clinical and scientific advisors
Helping Great Companies Grow

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

CONTACT US

Hi. We're not around right now. But you can send us an email and we'll get back to you, asap.

Thanks, Ken

Ken Margolis | Managing Partner Castle Placement, LLC
1460 Broadway Street, Rte 400
New York, New York 10036
(212) 418-1188 | C: (516) 712-7784
kmargolis@castleplacement.com

Sending

Log in with your credentials

Forgot your details?

Skip to toolbar